IN8bio, Inc. (INAB) vs Obsidian Therapeutics Inc. (OBX)

A side-by-side comparison of IN8bio, Inc. and Obsidian Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

INAB

IN8bio, Inc.

$14M

$1.43HealthcareDelayed quote: Oct 6, 2026, 11:29 AM EDT

OBX

Obsidian Therapeutics Inc.

$15M

$13.97HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

Total return — INAB vs OBX

growth of $100 · dividends reinvested · last 1y

INAB +18.3% (+18.3%/yr)OBX -20.9% (-20.9%/yr)INAB compounded faster over this window

INAB OBX

Metrics side by side

Total return (annualized)

Metric	INAB	OBX
Total return (1Y)	-40.44%	N/A
Total return CAGR (3Y)	-63.57%	N/A
Total return CAGR (5Y)	-62.88%	N/A

OBX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full INAB analysis Full OBX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.